Business
Hikma Pharmaceuticals PLC - Voting Rights and C...
Hikma Pharmaceuticals PLC - Voting Rights and C....
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \n\n\n\nLONDON, 4 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX:\nHIK) notifies the market that as at 31 March 2008 its capital\nconsists of 188,301,796 ordinary shares with voting rights. There are\nno shares held in treasury.\n\nThe above figure (188,301,796) may be used by shareholders as the\ndenominator for the calculations by which they will determine if they\nare required to notify their interest in, or a change to their\ninterest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and\nTransparency Rules.\n\nEnds -\n\nEnquiries:\n\nHikma Pharmaceuticals PLC\nHenry Knowles +44 20 7399 2760\nCompany Secretary\n\n\nAbout Hikma\nHikma Pharmaceuticals PLC is a fast growing multinational group\nfocused on developing, manufacturing and marketing a broad range of\nboth branded and non-branded generic and in-licensed pharmaceutical\nproducts. Hikma's operations are conducted through three businesses:\n\"Branded\", \"Injectables\" and \"Generics\". Hikma's operations are based\nprincipally in the Middle East and North Africa (\"MENA\") region,\nwhere it is a market leader and sells across 17 countries, the United\nStates and Europe. In 2007, the Group achieved revenues of $449\nmillion (2006 $317 million) and profit attributable to\nshareholders of $63 million (2006 $55 million). For news and other\ninformation, please visit www.hikma.com.\n\n---END OF MESSAGE---\n ","length":1396,"tagName":"div"}]